A Phase 2 interventional study of HIFU hemi-ablation combined with ADT. in Prostate Cancer and Androgen Deprivation Therapy, sponsored by Institut Mutualiste Montsouris. Completed at 1 site in France. Open to male participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Institut Mutualiste Montsouris · Phase 2, Interventional, and Prevention
The current study aims to examine the hypothesis that combining the focal effects of HIFU with the systemic effects of androgen deprivation therapy might eradicate the prostatic cancer cells by targeting the 'visible' index focus (by HIFU) and the tumour surrounding microenvironment which may contain 'invisible' foci and aberrant PCa related signalling (by androgen deprivation therapy) to enhance oncological outcomes of HIFU hemi-ablation in men with localized PCa, and consequently reducing treatment failures.
Prostate Cancer (PCa) is a multifocal disease in up to 90% of men with heterogeneity among different cancer foci in the same prostate gland. An index/dominant lesion has been proposed, namely the largest tumor nodule that often correlates with the highest Gleason score (GS) and, consequently, with the clinical behavior of the tumor. However, this concept is not always applicable as highest GS, largest tumor volume and extraprostatic extension may be present in different PCa foci in up to 10% of the cases.
Focal therapies (FT) for localized PCa emerged to reduce the adverse effects of radical treatments,including a30-90% for erectile dysfunction and 5-20% for incontinence and rectal toxicity, while maintaining comparable oncological efficacy. Amongst organ-sparing strategies, high-intensity focused ultrasound (HIFU) is widely used and yields promising cancer control rates and relatively low morbidity.
In our recently published prospective study of HIFU hemiablation for localized PCa with one year follow up, 25.4% of patients demonstrated PCa cores at 12 months post-treatment biopsy (Feijo et al, Eur Urol, 2016). Among them 11.5% of patients showed cancer in the contralateral untreated lobe. At 3 months, all patients were continent and 11 out of 21 preoperatively potent patients maintained adequate sexual functions. Minor adverse effects were reported in 8%, while 2.8% of patients experienced Clavien-Dindo grade-3 events.
Although FT has proven to be effective and less morbid treatment for localized PCa, an area for improvement still exists and a gap in cancer control needs to be filled by adding additional form of treatment so as to improve oncological outcomes and minimize treatment failures.
Research Rationale Previous studies have shown approximately 20% of men continue to harbour cancer at 12 months after HIFU FT for localized PCa. This finding could be in part attributed to undetectable (invisible) remote cancer foci owing to limitations of the currently available imaging and biopsy techniques and representing an appealing argument against FT.
Another point is tumor microenvironment, defined as the myriad of multiple interactions amongst tumour and surrounding cells including immune cells, stromal fibroblasts, mesenchymal stem cells and blood vessels.
It is not completely clear whether at least part of FT recurrences may be related to non-aggressive lesions taking the position of an index PCa focus and/or PCa index lesion signalling altering benign tissues behaviour.
Androgen deprivation therapy (ADT) modifies tumour microenvironment and suppresses PCa growth and progression.
Short-term ADT has been reported to increase the overall survival in men with localized intermediate- to high-risk PCa when combined with external beam radiation therapy (EBRT) or RP.
Short term ADT has been also investigated in the context of active surveillance; other trials are under way.
However, to date, there is no prospective data assessing the role of HIFU/ADT combination therapy for the treatment of localized PCa in terms of cancer control.
The current study aims to examine the hypothesis that combining the focal effects of HIFU with the systemic effects of androgen deprivation therapy might eradicate the prostatic cancer cells by targeting the 'visible' index focus (by HIFU) and the tumour surrounding microenvironment which may contain 'invisible' foci and aberrant PCa related signalling (by androgen deprivation therapy) to enhance oncological outcomes of HIFU hemi-ablation in men with localized PCa, and consequently reducing treatment failures, without significantly increasing toxicity and/or complications.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 19 is below the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Institut Mutualiste Montsouris is the lead sponsor of 35 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
Drug: HIFU hemi-ablation combined with ADT.
Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly. Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone \[LHRH\] agonist). The ADT protocol starts within 1 month prior to the scheduled HIFU session
Oncological outcome
Number of treatment failures determined after prostatic biopsy and defined as: * Any Gleason pattern ≥4. * Any Gleason score ≥7.
Time frame: 12 months after the HIFU session
Urinary continence
Rate of men maintaining continence and becoming incontinent after treatment. Continence is defined as \>0pad/day being used. Incontinence is defined conversely.
Time frame: 1, 3, 6 and 12 months post-treatment
Urinary continence variation
Variation of ICSmale SF score in incontinence domains (international continence society male short form questionnaire - incontinence domain is composed by six questions going from 0 (total continence) to 24 (severe incontinence).
Time frame: at 1, 3, 6 and 12 months post-treatment
Urinary continence proportion
Variation in continence category according to the number of pads used/day due to continence problems compared to baseline. Categories will be (full continence= 0 pads/day or security pad, mild incontinence =1pad/day, moderate incontinence= 2pads/day, severe incontinence \>2pads/day).
Time frame: 1,3, 6, and 12 months post-treatment
Urinary voiding function variation
Urinary voiding function variation (compared to baseline) assessing changes of the IPSS (International Prostatic Symptoms Score). The IPSS score measures if the subject has significant problems/symptoms in passing the urine/voiding the bladder. The scale goes from 0 (no symptoms or bother) to 35 (extremely severe symptoms).
Time frame: 1,3, 6, and 12 months post-treatment
Erectile function
Rate of men maintaining potency after treatment. Erectile function changes will be assessed using the IIEF-5 and considering potency as IIEF-5 ≥22 without need of any medication (PDE-5 inhibitors and/or others).
Time frame: 1, 3, 6 and 12 months post-treatment
Erectile function variation
Erectile function as compared to baseline using: * IIEF-5 score changes at different time points post-treatment, as compared to baseline. * Proportion of men who are potent at baseline and then sustain erectile dysfunction, at 12 months. Potency is defined as an IIEF score ≥22 without requiring any medication.
Time frame: at 1, 3, 6 and 12 months post-treatment
Ejaculatory function
Ejaculatory function compared to baseline using MSHQ-EjD questionary at time points post-treatment.
Time frame: 1, 3, 6 and 12 months post-treatment as compared to baseline.
Treatment toxicity and complications
Rate of men experiencing treatment related complications and toxicity. Surgical complications will be graded using the Clavien-Dindo classification. Treatment related toxicity and adverse events will be graded using the Common Terminology Criteria for reporting Adverse Events (CTCAE v5).
Time frame: 12 months
Additional treatment due to recurrent or persistent prostate cancer
Rate (%) of men needing to undergo further prostate cancer active treatment due to treatment failure due to biochemical recurrence according to the Phoenix criteria and biopsy proving persistence/recurrence of clinically significant PCa (defined as previously described - see Oncological outcome).
Time frame: 12 months
Quality of life variation
Evolution of quality of life compared to baseline at timepoints post-treatment using EQ-5D-5L questionary.
Time frame: 1, 3, 6 and 12 months post-treatment.
PSA variation
Serum free and total PSA levels changes
Time frame: at 1, 3, 6, and 12 months post-treatment, as compared to baseline.
Testosterone variation
Serum Testosterone levels changes .
Time frame: at 1, 3, 6, and 12 months post-treatment, as compared to baseline
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Mutualiste Montsouris